TrialDiabetes, obesity & metabolism2025

Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.

Emily R Hankosky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.